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Summary: Creatine kinase isoenzyme MB catalytic activities in human serum, determined by ACA ion ex-
change chromatography and immunoinhibition, differ significantly, the correlation coefficient being 0.88. The
reasons for this Variation are
1. interference of antibodies with the creatine kinase B subunit in the immunoinhibition assay,
2. nonreproducible elution of creatine kinase isoenzyme MB from the ion exchange resin in the ACA pack,
due to varying protein concentrations in the serum samples and
3. increasing elution of creatine kinase isoenzyme MM from the ion exchange column caused by a preceding
partial inactivation of creatine kinase isoenzyme MM.
Pretreatment of serum samples with a solution containing magnesium sulphate, maleate and 2-oxoglutarate
(solution A) prior to determination of creatine kinase isoenzyme MB catalytic activities on the ACA signifi-
cantly improves the sensitivity and specificity of the method; the correlation coefficient for the values from the
ACA and immunoinhibition then becomes 0.92. Dilution of serum samples with bovine serum albumin solu-
tion is now practicable.
Bestimmung der katälytischen Aktivität von Kreatinkinase Isoenzym MB mit dem ACA:
Abhängigkeit von der Serummatrix und anderen Effektoren
Zusammenfassung: Die mit der ACA-Methode (lonenaustauschchromatographie) und der Immunoinhibi-
tionsmethode bestimmten katälytischen Aktivitäten von Kreatinkinase Isoenzym MB in humanen Serumpro-
ben unterscheiden sich signifikant voneinander, so daß beim Vergleich der vom ACA erhaltenen Werte mit
denen der Immuninhibitionsmethode 0,88 als Korrelationseffizient erhalten wird. Die Ursachen dieser Diffe-
renz sind
1. eine Interferenz der Antikörper mit der Kfeatinkinase-Untereinheit B im Immunoinhibitionsansatz,
2. eine nicht reproduzierbare Elution des Kreatinkinase-Isoenzyms MB von der lonenaustausch-Säule im
ACA-Pack, verursacht vor allem durch unterschiedliche Proteinkonzentrationen in der Serumprobe und
3. eine zunehmende Kreatinkinase-Isoenzym MM-Elution von der lonenaustausch-Säule, verursacht durch
eine vorausgegangene partielle Inaktivierurtg dieses Isoenzyms.
Eine Vorbehandlung der Serumproben mit einer Lösung, die Magnesiumsulfat, Maleinsäure und Oxoglutar-
säure enthält (Lösung A), verbessert wesentlich die Bestimmung der katälytischen Aktivitäten von Kreatinki-
nase Isoenzym MB init dem ACA. Der dabei erhaltene Korrelationskoeffizient des Vergleichs der ACA-Me-
thode mit der Immunoinhibitionsmethode beträgt 0,92. Verdünnungen der Serumprobe mit einer Rinderse-
rum-Albuminlösung sind möglich.
*) This report contains essential parts of the dissertation of C. Kaul-Kunz.
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Introduction
The myocardium is the only tissue containing rela-
tively large amounts of creatine kinase (EC 2.7.3.2)
isoenzyme MB (CK-MB). Diagnosis of myocardial
injury therefore is generally possible from the ap-
pearance of this isoenzyme in the plasma together
with the corresponding clinical Symptoms (1). The
use of creatine kinase isoenzyme MB activity in the
diagnosis of myocardial infarction is thus well estab-
lished (2).
Numerous methods are available for measuring the
isoenzymes of creatine kinase (3, 4), each method
having a different sensitivity and specificity. These
include electrophoretic Separation (5), ion exchange
column chromatography (6), the immunoinhibition
assay (7) and the radioimmunoassay (8). While elec-
trophoresis and ion exchange column chromatogra-
phy give complete Separation of the three isoen-
zymes they aire cumbersome and only adequate for
detecting creatine kinase isoenzyme MB catalytic ac-
tivities at peak values. A Variation of ion exchange
column chromatography is the method used by the
ACA (Du Pont), in which a mixed anion-cation ex-
change chromatography column is used with a pH
near the isoelectric point of creatine kinase isoen-
zyme MB so that most of the enzyme is not retained
by the ion exchange resin (9). Its activity is then de-
termined automatically in the eluate. Electrophore-
sis and radioimmunoassay are not practical for gen-
eral laboratory use, but the immunoinhibition meth-
od and the ACA method are in conimon use.
However, a reevaluation of the ACA method was
necessary because the correlation between the crea-
tine kinase isoenzyme MB catalytic activities ob-
tained by the ACA and immunoinhibition methods
is only partial (10).
Quantitative determination of reduced NADP+ in the creatine ki-
nase isoenzyme bands was carried out fluorometrically, using a
Zeiss PMQ-II spectrophotometer (Fa. Zeiss, Oberkochen, Ger-
many) (excitation at 340 nm, reflected emission at 450 nm).
Total creatine kinase catalytic activity was measured on the ACA
II (starting point = 0, scale factor = 0.6228). Creatine kinase MB
catalytic activities were determined on the ACA II (starting point
= 0, scale factor = 0.6068 or 0.8422 or 0.3096) and with the
immunoinhibition method (10 min preincubation, filter 365 nm,
photometer Eppendorf, 25 °C). Solution A contained 1.5 mol/l
magnesium sulphate, 25 mmol/l maleic acid and 1.25 mmol/I oxo-
glutaric acid. The sample was mixed with solution A in a ratio of
1+9 prior to measurement of creatine kinase isoenzyme MB cata*
lytic activities on the ACA.
The serum samples used in this assay were obtained from different
persons from the intensive care unit without special selection. The
lowest and highest total creatine kinase catalytic activity concen-
tration measured was 98 U/l and 4810 U/l. Diagnosis of acute
myocardial infarction was by electrocardiogram with the excep-
tion of one case, which was diagnosed from serum enzyme catalyt^
ic activities.
Isoelectric focussing of purified creatine kinase isoenzymes MM
and MB was carried out with a LKB 110 ml column (Ampholine
pH 3—7) according to the LKB instruction manual.
Effectors were added to serum or to bovine serum albumin con-
taining samples in a volume ratio of 1+9.
Creatine kinase catalytic activities at 37 °C were converted to ac-
tivities at 25 °C by multiplying by 0.42 (13).
The coefficients of Variation (N = 25) for the methods were äs
follows: immunoinhibition method creatine kinase MB 8.8% (35
U/l), electrophoresis creatine kinase MB 11.8% (22 U/l), ACA
creatine kinase MB 6.0% (50 U/l), ACA creatine kinase MB with
sample pretreatment by solution A 5.4% (56 U/l), ACA creatine
kinase 5.7% (70 U/1).
Monotests for determination of creatine kinase isoenzyme MB ca-
talytic activities with the immunoinhibition method were obtained
from Fa. Boehringer, D-6800 Mannheim and Fa. Merck, D-6100
Darmstadt, Germany. Aspartate.aminotransferase (EC 2.6.1.1),
alanine aminotransferase (EC 2.6.1.2) and adenylate kinase (EC
2.7.4.3) from porcine heart, glutamate dehydrogenase (EC
1.4.1.3) from bovine liver, human immunoglobulin G, organic
and inorganic reagents and Substrates were commercial prepara-
tions from Fa. Boehringer, Fa. Merck, Fa. Sigma, D-8000 Mün-
chen and Fa. Serva, D-6200 Heidelberg.
The comparision of the analytical procedures was carried out us^
ing the standardized principal component analysis.
Materials and Methods
The creatine kinase isoenzyme MB from human myocardium was
purified according to I.e. (11) with the modification that all Steps
were carried out in the presence of l mmol/l EGTA. The purified
creatine kinase isoenzyme MB preparation was homogeneous äs
judged by disc gel electrophoresis (12) and contained no detecta-
ble creatine kinase isoenzyme MM (CK-MM) catalytic activity äs
shown by electrophoresis on cellulose acetate Strips (5). Human
creatine kinase isoenzyme B B was obtained by homogenization of
10 g uterus muscle in 100 ml of 0.05 mol/l Tris-HCl buffer pH 7.4
and 10000g centrifugation. The supernatant contained a pure
creatine kinase isoenzyme BB preparation äs judged by electro-
phoresis on cellulose acetate Strips (5).
Electrophoresis was carried out according to I.e. (5) with several
modifications: 0.05 mol/l barbituric acid buffer pH 8.6, time of
electrophoresis 30 min at 25 °C, development of creatine kinase
bands in the cellulose acetate Strips at 37 °C for 30 min on 2 g agar
in 100 ml H2O, mixed with CK-monotest at a ratio of 1 + 1 (vol/
vol).
Results
Effects of inatrix compositiön on the crea-
tine kinase isoenzyme MB determination
by the ACA method
Constituents tested
Several constituents normally present in plasma
were tested for their effect on the ACA method, üs-
ing concentrations exceeding the normal fange. H+-
concentration (pH 7.6, pH 7.2) lactic acid (6.0
-mmol/l), cholic acid (400 mg/1), cholesterol (2 g/l),
bilirubin (10 mg/1), protoporjjhyrin (50 g/l), glu-
tamate dehydrogenase (4000 U/l), aspartate amino-
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transferase (4000 U/l), alanine aminotransferase
(4000 U/1) and adenylate kinase (4000 U/l) did not
modify the ACA creatine kinase MB values when
added to purified creatine kinase MB in bovine se-
rum albumin Solutions (80 g/l).
A human serum pool containing varying Contents of
added creatine kinase isoenzymes BB or MM and
containing no creatine kinase MB catalytic activity
was tested by the ACA creatine kinase MB method
(tab. 1). Creatine kinase MM is retained (99%) by
the ACA column, creatine kinase BB is partially
(19—40%) eluted so that falsely high creatine kinase
MB catalytic activities are obtained.
Tab. 1. Effects of human creatine kinase MM and BB on the
creatine kinase MB assay on the ACA. The enzymes
were added in the indicated catalytic activity concentra-
tion (25 °C) to a human serum pool containing no crea-
tine kinase activity. The creatine kinase MB activity was
determined on the ACA with the factor 0.6068 and was
then corrected to 25 °C by the factor 0.5829.
Catalytic Catalytic
concentration concentration
added measured by
ACA (U/l)
(U/1,25°C) Control After
dilution
by
solution A
Creatine kinase MM
Creatine kinase BB
1424
98
77
57
38
18
8
35
25
15
10
3
9
29
23
15
9
4
The only other known constituent which significantly
irifluences the creatine kinase MB values obtained
by the ACA is total protein. It modifies the retention
of creatine kinase MB on the ion exchange column in
the ACA pack (fig. 1), Increasing plasma protein or
bovine serum albumin or human ifrimunoglobulin G
conce trations cause an appropriate increase of
creatine kinase elution from the column s indicated
by increased catalytic concentrations measured by
the ACA (an increase of l g/l serum protein corre-
sponds to an increase of l U/l, ACA factor 0.6068).
Other nknown constit ents present in human se-
rum modify· the elution of creatine kinase from the
ACA column. Therefore, a dilution of serum is not
possible, even if a solution of bovine serum albumin
is used for dilution (fig. 2).
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Fig. 1. Dependence of ACA creatine kinase determination on
the protein concentration in the serum sample. Purified
creatine kinase MB (49 U/l, determined in the ACA total
creatine kinase channel, 25 °C) was added to human se-
rum samples. χ—χ control, O—O sample pretreatment by
solution A. Catalytic concentration was measured with the
ACA factor 0.6068 and was converted to 25 °C by the
factor 0.5829.
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Fig. 2. Dependence of creatine kinase determination by the ACA
on the dilution of serum samples. Purified creatine kinase
MB (49 U/l, 25 °C) was added to a human serum sample,
which was diluted with a bovine serum albumin solution
(80 g/l) s indicated. O—O control, D—D with sample
pretreatment by solution A. The catalytic concentration
was measured with the ACA factor 0.6068 and was then
converted to 25 °C by the factor 0.5829.
Influence of solution A on creatine kinase MB deter-
mination by the ACA method
When commercially available porcine heart aspar-
tate aminotransferase was tested for its effect on the
determination by the ACA it was observed that the
obtained values were in good agreement with the
creatine kinase activities added to the matrix. This
improved elution from the ACA column, however,
was not caused by the aspartate aminotransferase
but by the stabilization mixture present in the aspar-
tate aminotransferase solution. This mixture consist-
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ed of ammonium sulphate, maleate and 2-oxoglutar-
ate. After exchanging ammonium sulphate for mag-
nesium sulphate this solution A was tested for its in-
fluence on the determination of creatine kinase ac-
tivities in human serum by the ACA (figs. 1—3,
tab. 1).
Addition of solution A to serum samples reduces the
effects of serum protein (fig. 1) and other serum con-
stituents (fig. 2) on creatine kinase MB determina-
tion by the ACA. Dilution of serum samples with
bovine serum albumin Solutions, containing 80 g/l
protein, is now possible when the diluted sample is
pretreated with solution A. No effect of solution A
on the elution of creatine kinase MM or MB is ob-
served (tab. 1).
1.00
0.80
0.60
g 0.40
0.20
0.00 ) 9.375 18.75 37.5 75 150 300
MgS04 [mmol/l]
0 0.156 0312 0.625 1.25 25 5
Maleate[mmol/l]
0 0.0078 OD156 0.031 0.0625 0.125 0.25
2-Oxoglutarate [mmol / l ]
Fig. 3. Effects of pretreatment of samples with different concen-
trations of substances contained in solution A. Purified
creatine kinase MB (49 U/l, 25 °C) was added to a bovine
serum albumin solution (80 g/l). The catalytic concentra-
tion was measured on the ACA with the factor 0.6068 and
was then converted to 25 °C by the factor 0.5829.
When serum samples containing added purified
creatine kinase MB and creatine kinase MM are in-
cubated at room temperature for several days, an ap-
parent increasing creatine kinase MB catalytic activi-
ty is measured by the ACA (tab. 2). This is due to
the creatine kinase MM present in the serum matrix
or due to the added creatine kinase, which is not
completely retained by the ion exchange column.
After sample pretreatment with solution A this in-
creased elution of creatine kinase MM from the co-
lumn in the ACA pack, is not observed.
Tab. 2. Effects of inactivation of creatine kinase MM on the de-
termination of creatine kinase MB in human serum.
140 U/l (25 °C) creatine kinase MM was added to a hu-
man serum pool. After the indicated incubation time at
25 °C total creatine kinase and creatine kinase MB cata-
lytic activities were measured on the ACA (factor
0.3096) with and without sample pretreatment by solu-
tion A. Above values were calculated by subtractmg the
measured activities of the native serum pool from the ac-
tivity values obtained after addition of creatine kinase
MM.
Days of incubation
0 2 7
Total creatine kinase
Creatine kinase MB
Total creatine kinase
Creatine kinase plus
solution A pretreatment
(U/l)
(U/l)
(U/l)
(U/l)
139
4
140
4
140
6
140
4
123
10
115
4
Correlation of the immunoinhibition and the ACA
method
The correlations of creatine kinase MB catalytic ac-
tivities in the serum of 28 patients suffering from
acute myocardial infarction measured by the immu-
noinhibition method (25 °C) and the ACA methods
(25 °C) are shown in figures 4—7b and table 2. The
values obtained by the ACA method (37 °C) with
the original factor 0.6068 are too low for a tempera-
ture of 37 °C. Later, Du Pont corrected this factor
from 0.6068 to 0.8422. When the creatine kinase
MB catalytic activities are converted firöin factor
0.6068 to 0.8422 and are multiplied by 0.42 (13)
(factor 0.5829) then the activities for a temperature
of 25 °C are obtained. A comparison of these values
with the activities obtained by the immunoinhibition
rnethod shows good agreement in slöpe (1.0), but
the correlatioii coefficient is only 0.88 (fig. 4). Addi-
tion of solution A to the serum samples increases the
slope (immunoinhibition method versus ACA meth-
od at 25 °C) to 1.29 and the correlation is iinproved
to 0.92 (fig. 5).
When human serum samples containing varying ca-
talytic activities of added purified creatine kinase
MB are measured on the ACA in the total creatine
kinase channel (25 °C) and in the creatine kinase
MB channel (factor 0.3096) after pretreätment with
solution A, values for total creatine kinase and crea-
tine kinase MB are identical. Following the correc-
tion of creatine kinase MB activities obtained for the
28 serum samples after pretreatment with solution
A, using the faetor 0.3096 instead of 0.6068, the
values compare well with the activities obtained by
the immunoinhibition (fig. 6); The slope is now 1.03,
the coefficient of correlation tf.92.
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Fig. 4. Samples: human serum ffom persons suffering from an Fig. 6. Correlation s in fig. 4. Samples were pretreated with so-
acute myocardial infarction. Conrelation of creatine kinase lution A prior to determination of catalytic concentration
MB values obtained by the immunoinhibition niethod on the ACA (factor 0.3096).
(25 °C) and the ACA method s described in fig. 3.
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Fig. 5. Correlation s in fig. 4. The samples were pretreated with Fig. 7. Residual creatine kinase activity of a creatine kinase MB
solution A prior to determination of catalytic concentra- preparation added to bovine serum albumm (80 g/l)
(B—·) and to a human serum pool (D—D) in depend-
ence of the anti-creatine kinase MM antibody concentra-
tion, s determined by the immunoinhibition method. The
varying antibody concentration was obtained by mixing
creatine kinase and creatine kinase MB monotests s indi-
catcd.
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Inhibition of creatine kinase B subunit by anti-crea-
tine kinase MM antibodies
During the purification procedure of human heart
creatine kinase MB it was observed that the creatine
kinase catalytic MB activities obtained by the immu-
noinhibition method were always lower than the
values measured by the total creatine kinase method,
even when the creatine kinase MB preparations con-
tained no detectable isoenzyme MM activity. This
discrepancy was caused by a partial Inhibition of
creatine kinase B subunit by the anti-creatine kinase
MM antibodies present in the immunoinhibition test
(fig. 7). This Inhibition is also observed when prepa-
rations are preincubated in 200 mmol/ N-acetylcys-
teine and when creatine kinase MB preparations
were used which had been separated from creatine
kinase isoenzyme MM by a single purification step
(human heart homogenate was applied to DEAE-
Sepharose A 50 and creatine kinase MB was eluted
according to . . (11)).
Discussion
The original ACA method for determination of
creatine kinase MB catalytic activities shows several
limitations. Dilution of the samples is not possible
and 30—40% of the creatine kinase MB in the serum
sample is retained on the column (9) so that a cor-
rection of the obtained values is necessary.
When using the immunoinhibition method for mea-
surement of creatine kinase MB activities it must be
presupposed that the creatine kinase B subunit re-
mains active after incubation of the serum with the
creatine kinase MM antibodies. This cannot be gua-
ranteed äs is seen in figure 7, where an apparent
20% Inhibition of the purified creatine kinase B sub-
unit by creatine kinase MM antibodies is observed.
The same Inhibition by creatine kinase MM antibo-
dies is observed when creatine kinase MB prepara-
tions are used which have been separated from the
creatine kinase MM by a single chromatography
step, thus largely preventing possible denaturation of
the creatine kinase B molecule. Use of monotests for
the immunoinhibition method from another com-
mercial source yielded identical results. Similar ob-
servations have been reported by other authors (14).
It is not clear whether the antibodies against the
creatine kinase M subunit present in the immunoin-
hibition monotest inhibit the creatine kinase B sub-
unit in native serum äs well.
If an Inhibition of creatine kinase B subunit is ex-
cluded, then the above described effects must be ex-
plained by different turnover numbers of the subun-
its M and B, and may be based on a differential
course of inactivation of the subunits. It is known
that the thermolability of the creatine kinase isoen-
zymes increases in the order creatine kinase isoen-
zyme MM, MB and BB (15). This preferential inac-
tivation of the creatine kinase B subunits also occurs
in vivo (16) and results in a shift of remaining cata-
lytic activity toward creatine kinase MM. In either
case, use of the immunoinhibition method for deter-
mination of creatine kinase MB catalytic activities is
limited to serum samples where the creatine kinase
subunit B activity is not affected, i.e. to serum sam-
ples from persons suffering from a fresh acute myo-
cardial infarction. It is known (21) that the concen-
tration of creatine kinase B remains elevated lortger
than its catalytic activity, and that the elimination ki-
netics for catalytic activity and concentratiön are dif-
ferent.
In addition, an increased creatine kinase B value
from the immunoinhibition method might be diffi-
cult to Interpret, if creatine kinase BB is also possibly
present in the plasma. While most diseases leading to
activities in plasma do not present a difficult diag-
nostic problem in relation to acute myocardial in-
farction (17), this is not true in the case of anoxic
brain injury after cardiac arrest (18). If creatine ki-
nase BB is present in serum samples which are tested
for creatine kinase MB activity, the values derived
from the immunoinhibition method are falsely in-
creased by 200% of the residual creatine kinase BB
activity, whereas the creatine kinase MB values ob-
tained by the ACA are only, increased by 22—29%
of the residual creatine kinase BB activity.
While the ACA method is not disturbed by many of
the metabolites present in plasma (tab. 1), the total
protein content in the sample is decisive in obtaining
acceptable values. Differences in plasma protein
concentratiön is one of the reasons for a variable re-
tention of creatine kinase MB on the ion exchange
column. This was first shown by I.e. (19) and later in
greater detail by I.e. (20).
When solution A is added to the samples, the deter-
mination of creatine kinase catalytic activity on the
ACA is significantly improved and reproducible
values are obtained. The effect of protein concentra-
tiön in the serum sample is eliminated and dilution of
serum samples with a bovine serum albumin solution
is possible. Of all the methods compared, the best
diagnostic sensitivity and specificity are obtained
with the inodified ACA method (fig. 6, tab. 3) and a
significant Separation is observed of the infarction
-samples (fig. 8). There are two reasons for the im-
provement of the ACA creatine kinase MB determi-
nation due to pretreatment with solution A. Since
J. Clin. Chem. Clin. Biochem. / Vol. 22,1984 / No. 11
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Fig. 8. Histogram of frequency of creatine kinase MB catalytic activity expressed s fraction of total creatine kinase activity. Samples
from patients without ( ) and with (-—) acute myocardial infarction. N = 79. The diagnostic decision limit for acute
myocardial infarction is a creatine kinase activity fraction of 0.06.
a. Determination of catalytic concentration on the ACA (factor 0.6068, corrected to 25 °C by factor 0.5829). Sensitivity 0.87,
specificity 0.667, predictive value positive test - p.v. (+) - 0.627, predictive value negative test - p. v. (-) - 0.89.
b. Determination of catalytic concentration on the ACA (factor 0.6068, corrected to 25 °C by factor 0.5102) with sample
pretreatment by sohition A. Sensitivity 0.87, specificity 0.812, p.v. (+) 0.743, p. v. (-) 0.901.
c. Determination of catalytic concentration by the immunoinhibition method (25 °C). Sensitivity 0.935, specificity 0.729, p. v.
(+) 0.69, p. v. (-) 0.?46.
addition of N-acetylcysteine to the serum samples
has an effect simil r to the addition of solution A, an
activatipn of creatine kinase MB with an improved
elution from the column might be occurring. Second-
ly, additional sample pretreatment causes an in-
Tab. 3. Comparison of an lytical methods (y = bx -f a).
IIM = immunoinhibition method.
Compared methods N χ y Sxy f a b
IIM (25 °C)/ACA-MB 28 29 24 694 0.88 -5.97 1.0
factor 0.6068, corrected
by factor 0.5829
IIM (25 °C)/ACA-MB 28 29 31 899 0.92 -6.68 1.29
-f- sol. A, factor 0.6068,
corrected
by factor 0.5829
IIM (25 °C)/ACA-MB 28 29 25 725 0.92 -5.31 1.03
-l· sol. A, factor 0:3096
creased retention of creatine kinase MM on the co-
lumn in the ACA pack s seen in table 2. After incu-
bation of purified creatine kinase MM/MB combina-
tions in serum matrix for several days at room
temperature, increasing amounts of creatine kinase
MM are eluted from the column, so that apparently
higher creatine kinase MB activities are measured.
The ACA ion exchange chromatography is carried
out at pH 6.1 and the isoelectric points of human
creatine kinase isoenzymes MM and MB are 6.95
and 4.85, respectively. The partial inactivation of
creatine kinase MM causes a shift of isoelectric point
toward pH 6. l s judged by a slightly faster migra-
tion of this partially inactivated creatine kinase MM
in electrophoresis. As a result this modified creatine
kinase MM is not retained s completely by the co-
lumn s the fully active creatine kinase MM. We
must assume that simil r effects occur in vivo (16),
so that sometimes falsely high creatine kinase MB
activities are measured by the original ACA method.
J. Clin. Chem. Clin. Biochem. / VoL 22,1984 / No. 11
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